✉news BusinessStartups first seen 20 h ago, last 50 min ago, peak #3
Shionogi to pay $2 billion for rare disease startup
Original: Shionogi pays $2B to acquire a rare disease startup
Japanese drugmaker Shionogi has agreed to acquire a rare disease-focused biotech startup in a deal worth roughly $2 billion. The acquisition, reported by BioPharma Dive, signals Shionogi's push to expand beyond its core infectious disease business into rare and specialty medicines, as larger pharma companies continue buying up innovative biotech pipelines.
Why now: Pharmaceutical dealmaking is drawing attention as established drugmakers race to acquire biotech pipelines.
Rank over time, top of the chart is #1. 15 snapshots from 20 h ago to 50 min ago.
Evidence
- Shionogi pays $2B to acquire a rare disease startup · BioPharma Dive
API: https://socialmediatrends-api.osmike.com/v1/trends/1135857